Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

AMPICILLIN

2 general benefit · 2 not a benefit

Other products in the same Health Canada class (J01C, J01CA) — coverage varies; not interchangeable

  • Amoxicillin (Novamoxin): general benefit, Not a benefit, Listing status unconfirmed
  • Amoxicillin + clavulanic acid (Clavulin): general benefit, Not a benefit
  • Cloxacillin (Orbenin): general benefit, Not a benefit
  • Penicillin v (Nadopen-V): general benefit, Not a benefit
  • Piperacillin + tazobactam (Tazocin): not a benefit

Novo-Ampicillin · DIN 00020877 · 250mg · capsule

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Novo-Ampicillin · DIN 00020877 Manufacturer: Novopharm Ltd.; listing date 1996-10-01 Daily cost (source): $1.6892 Health Canada: Marketed since 2015-07-10 · brand TEVA-AMPICILLIN · ATC J01CA01 AMPICILLIN · form Capsule · route Oral · ingredients AMPICILLIN (AMPICILLIN TRIHYDRATE) 250 MG · company Teva canada limited · schedule Prescription
Check this DIN again · Health Canada product record

Novo-Ampicillin: Formulary list price $0.4223/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.4223 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=1125 · Verify on the e-Formulary ↗ (DIN 00020877)

Source record
DIN 00020877: Novo-Ampicillin Raw flags: sec3=Y Item: 081216002; group id 27; item number 0055; lccId None; manufacturer id NOP Source form: Cap; strength: 250mg Recorded listing: General benefit Source prices (unrounded): $0.4223; ministry $0.4223 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00020877 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=1125
Interchangeable products
Penbritin · DIN 00002003 · not recorded
Shortage status: active shortage (reported 2026-02-11, last updated 2026-06-04); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00020877
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Novo-Ampicillin · DIN 00020885 · 500mg · capsule

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Novo-Ampicillin · DIN 00020885 Manufacturer: Novopharm Ltd.; listing date 1996-10-01 Daily cost (source): $3.2024 Health Canada: Marketed since 2015-07-10 · brand TEVA-AMPICILLIN · ATC J01CA01 AMPICILLIN · form Capsule · route Oral · ingredients AMPICILLIN (AMPICILLIN TRIHYDRATE) 500 MG · company Teva canada limited · schedule Prescription
Check this DIN again · Health Canada product record

Novo-Ampicillin: Formulary list price $0.8006/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.8006 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=1124 · Verify on the e-Formulary ↗ (DIN 00020885)

Source record
DIN 00020885: Novo-Ampicillin Raw flags: sec3=Y Item: 081216001; group id 27; item number 0056; lccId None; manufacturer id NOP Source form: Cap; strength: 500mg Recorded listing: General benefit Source prices (unrounded): $0.8006; ministry $0.8006 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00020885 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=1124
Interchangeable products
Penbritin · DIN 00002011 · not recorded
Shortage status: resolved shortage (ended 2023-11-08); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00020885
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Penbritin · DIN 00002003 · 250mg · capsule

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 1996-09-10 — choose a marketed DIN from the same-category list.Discontinued 1996-09-10 · checked 2026-09-02
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 1996-09-10 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 1996-09-10 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Penbritin · DIN 00002003 Manufacturer: Ayerst Laboratories, Division of Ayerst, McKenna & Harrison; listing date 1996-10-01 Daily cost (source): $1.6892 Health Canada: Cancelled post market since 1996-09-10 · brand PENBRITIN CAP 250MG · ATC J01CA01 AMPICILLIN · form Capsule · route Oral · ingredients AMPICILLIN 250 MG/CAP · company Ayerst laboratories · schedule Prescription
Check this DIN again · Health Canada product record

Penbritin: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=542 · Verify on the e-Formulary ↗ (DIN 00002003)

Source record
DIN 00002003: Penbritin Raw flags: notABenefit=Y, sec3=Y Item: 081216002; group id 27; item number 0055; lccId None; manufacturer id AYE Source form: Cap; strength: 250mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00002003 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=542
Interchangeable products
Novo-Ampicillin · DIN 00020877 · $0.4223
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00002003
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 1996-09-10 — choose a marketed DIN from the same-category list.

Penbritin · DIN 00002011 · 500mg · capsule

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 1996-09-10 — choose a marketed DIN from the same-category list.Discontinued 1996-09-10 · checked 2026-09-02
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 1996-09-10 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 1996-09-10 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Penbritin · DIN 00002011 Manufacturer: Ayerst Laboratories, Division of Ayerst, McKenna & Harrison; listing date 1996-10-01 Daily cost (source): $3.2024 Health Canada: Cancelled post market since 1996-09-10 · brand PENBRITIN CAP 500MG · ATC J01CA01 AMPICILLIN · form Capsule · route Oral · ingredients AMPICILLIN 500 MG/CAP · company Ayerst laboratories · schedule Prescription
Check this DIN again · Health Canada product record

Penbritin: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=538 · Verify on the e-Formulary ↗ (DIN 00002011)

Source record
DIN 00002011: Penbritin Raw flags: notABenefit=Y, sec3=Y Item: 081216001; group id 27; item number 0056; lccId None; manufacturer id AYE Source form: Cap; strength: 500mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00002011 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=538
Interchangeable products
Novo-Ampicillin · DIN 00020885 · $0.8006
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00002011
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 1996-09-10 — choose a marketed DIN from the same-category list.
Other drugs in the same formulary class (08:12:16 Penicillins) and how they are covered

Matched class: 08:12:16 Penicillins

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Some products covered without a code (check the product listing): AMOXICILLIN, AMOXICILLIN & CLAVULANIC ACID, CLOXACILLIN, PENICILLIN V (POTASSIUM) 08:12:16 Penicillins

AMOXICILLIN

· 36 products · General benefit (27), Listed, not a benefit (4), Off-Formulary Interchangeable, not an ODB benefit (4), Temporary benefit (1) · strengths: 250mg, 500mg, 125mg, 25mg/mL, 50mg/mL · Cap, Chew Tab, O/L, Pd for Oral Susp

AMOXICILLIN & CLAVULANIC ACID

· 25 products · General benefit (22), Listed, not a benefit (3) · strengths: 25mg & 6.25mg/mL, 50mg & 12.5mg/mL, 200mg & 28.5mg/5mL, 400mg & 57mg/5mL, 250mg & 125mg, 500mg & 125mg, 875mg & 125mg · O/L, Susp, Tab

CLOXACILLIN

· 8 products · Listed, not a benefit (3), General benefit (5) · strengths: 250mg, 500mg, 25mg/mL · Cap, O/L

PENICILLIN V (POTASSIUM)

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 25mg/mL, 300mg · O/L, Tab

PIPERACILLIN SODIUM & TAZOBACTAM SODIUM

· 18 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 2g & 250mg, 3g & 375mg, 4g & 500mg · Inj Pd-2.25g Vial Pk, Inj Pd-3.375g Vial Pk, Inj Pd-4.5g Vial Pk Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 08:12:16
Full class listing Related classes: 08:12:04 Antifungals, 08:12:07 Carbapenems, 08:12:12 Erythromycins, 08:12:24 Tetracyclines, 08:12:28 Other Antibiotics, 08:14:08 Azoles Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
Indications: The treatment of infections due to susceptible gram-negative organisms (including strains of shigellae, S. typhosa and other salmonellae, E. coli, H. influenzae and P. mirabilis) and susceptible gram positive organisms (including streptococci, pneumococci, and non beta lactamase producing staphylococci). To reduce the development of drug-resistant bacteria and maintain the effectiveness of TEVA- AMPICILLIN and other antibacterial drugs, TEVA-AMPICILLIN should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. https://pdf.hres.ca/dpd_pm/00057464.PDF PM date: not printed or not captured Source product: TEVA-AMPICILLIN; DIN 00020877; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Availability

Novo-Ampicillin · DIN 00020877 Shortage status: active shortage (reported 2026-02-11, last updated 2026-06-04); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00020877

Check this DIN again

Other review policies

For Penbritin: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026